Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Sold as Halog, Halog-E. Every FDA application for this active ingredient: 6 branded and 3 generic.
As of Nov 13, 2026, FDA lists 9 applications for Halcinonide (sold as Halog, Halog-E), first approved Nov 27, 1974, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Halcinonide | Part D | $1.4M | +45% | 593 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 27, 1974 | HalogNDA 17556 · New molecular entity | Sun Pharm Inds Inc | 28 | Marketed |
| May 4, 1977 | HalogNDA 17823 · New dosage form | Sun Pharm Inds Inc | 22 | Marketed |
| Jun 15, 1977 | HalogNDA 17818 · New dosage form | Westwood Squibb | 2 | Discontinued |
| Jun 15, 1977 | HalogNDA 17824 · New dosage form | Sun Pharm Inds Inc | 23 | Discontinued |
| Jan 24, 1980 | Halog-ENDA 18234 · New formulation or manufacturer | Sun Pharm Inds Inc | 20 | Discontinued |
| Aug 12, 2019 | HalcinonideANDA 211027 | Mylan | 0 | Marketed |
| Sep 8, 2021 | HalcinonideANDA 214723 | Chartwell Rx | 0 | Marketed |
| May 29, 2024 | HalcinonideANDA 217671 | Encube | 0 | Marketed |
| — | HalogNDA 18125 | Bristol Myers Squibb | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Bristol Myers Squibb